Drug safety evaluation of adefovir in HBV infection

Author： Viganò Mauro Lampertico Pietro Colombo Massimo

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.5, 2011-09, pp. : 809-818

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance

Current Medicinal Chemistry, Vol. 22, Iss. 34, 2015-11 ,pp. : 3922-11

Bentham Science Publishers

Access to resources Recommend Favorite

Adefovir monotherapy not for HBV + HIV co-infected patients

Reactions Weekly, Vol. 1, Iss. 1066, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Adefovir dipivoxil successfully suppresses HBV replication

Inpharma, Vol. 1, Iss. 1377, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Drug safety evaluation of defibrotide

By Richardson Paul G

Expert Opinion on Drug Safety, Vol. 12, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Drug safety evaluation of amlodipine

By Derosa Giuseppe Maffioli Pamela

Expert Opinion on Drug Safety, Vol. 10, Iss. 5, 2011-09 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite